Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compugen Ltd. stock logo
CGEN
Compugen
$2.04
$2.61
$1.29
$3.23
$192.89M2.74585,023 shs206,978 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$14.62
+1.7%
$12.42
$6.16
$16.73
$724.78M1.9991,421 shs502,102 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.88
+3.0%
$5.25
$1.50
$13.24
$711.78M0.916.86 million shs1.97 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.68
-3.2%
$3.22
$2.41
$6.55
$770.87M2.143.70 million shs2.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compugen Ltd. stock logo
CGEN
Compugen
+4.08%-8.11%-27.92%-8.93%+17.24%
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.64%-11.01%+10.28%+83.89%+108.10%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+1.77%-12.66%+110.76%+20.73%-11.86%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-1.77%-6.42%-15.03%-17.56%+2.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compugen Ltd. stock logo
CGEN
Compugen
$2.04
$2.61
$1.29
$3.23
$192.89M2.74585,023 shs206,978 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$14.62
+1.7%
$12.42
$6.16
$16.73
$724.78M1.9991,421 shs502,102 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.88
+3.0%
$5.25
$1.50
$13.24
$711.78M0.916.86 million shs1.97 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$2.68
-3.2%
$3.22
$2.41
$6.55
$770.87M2.143.70 million shs2.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compugen Ltd. stock logo
CGEN
Compugen
+4.08%-8.11%-27.92%-8.93%+17.24%
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.64%-11.01%+10.28%+83.89%+108.10%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+1.77%-12.66%+110.76%+20.73%-11.86%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-1.77%-6.42%-15.03%-17.56%+2.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Compugen Ltd. stock logo
CGEN
Compugen
2.80
Moderate Buy$5.00145.10% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.113.36% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
1.70
Reduce$4.88-45.10% Downside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.67
Moderate Buy$9.50254.48% Upside

Current Analyst Ratings Breakdown

Latest CGEN, CYRX, SANA, and REPL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingHold$13.00
6/3/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
DowngradeSell (D-)Sell (E+)
6/3/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $20.00
6/1/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Boost Price TargetNeutral$2.00 ➝ $6.00
5/29/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
UpgradeUnderweightNeutral$8.00
5/21/2026
Compugen Ltd. stock logo
CGEN
Compugen
Lower Price TargetOutperform$13.00 ➝ $5.00
5/20/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetOverweight$15.00 ➝ $17.00
5/11/2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
Initiated CoverageBuy$16.00
5/8/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
UpgradeSell (E+)Sell (D-)
5/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeSell (D+)Hold (C-)
(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Compugen Ltd. stock logo
CGEN
Compugen
$72.76M2.65$0.37 per share5.46$1.09 per share1.87
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.18N/AN/A$9.19 per share1.59
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Compugen Ltd. stock logo
CGEN
Compugen
$35.34M$0.375.51N/AN/A47.97%47.72%27.51%8/5/2026 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3510.83N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%6/12/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)

Latest CGEN, CYRX, SANA, and REPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/12/2026Q4 2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.73N/AN/AN/A$5.57 millionN/A
5/18/2026Q1 2026
Compugen Ltd. stock logo
CGEN
Compugen
-$0.07-$0.08-$0.01-$0.08$1.57 million$2.18 million
5/11/2026Q1 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.15-$0.14+$0.01-$0.17N/AN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Compugen Ltd. stock logo
CGEN
Compugen
N/A
6.23
6.23
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.33
5.60
5.60
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.29
1.29

Institutional Ownership

CompanyInstitutional Ownership
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Replimune Group, Inc. stock logo
REPL
Replimune Group
5.20%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
25.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Compugen Ltd. stock logo
CGEN
Compugen
7094.55 million85.57 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21082.57 million78.28 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
380278.29 million207.61 millionOptionable

Recent News About These Companies

Sana Biotechnology (SANA) Receives a Buy from Wedbush
Sana: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Compugen stock logo

Compugen NASDAQ:CGEN

$2.04 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.12 +0.08 (+3.92%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$14.62 +0.24 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$14.79 +0.17 (+1.16%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$8.88 +0.26 (+3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$8.85 -0.04 (-0.39%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$2.68 -0.09 (-3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$2.70 +0.02 (+0.75%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.